Plus Therapeutics Statistics
Share Statistics
Plus Therapeutics has 5.90M shares outstanding. The number of shares has increased by 37.89% in one year.
| Shares Outstanding | 5.90M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.75M |
| Failed to Deliver (FTD) Shares | 762 |
| FTD / Avg. Volume | 0.99% |
Short Selling Information
The latest short interest is 52.34K, so 0.89% of the outstanding shares have been sold short.
| Short Interest | 52.34K |
| Short % of Shares Out | 0.89% |
| Short % of Float | 0.91% |
| Short Ratio (days to cover) | 0.98 |
Valuation Ratios
The PE ratio is -0.41 and the forward PE ratio is -0.63.
| PE Ratio | -0.41 |
| Forward PE | -0.63 |
| PS Ratio | 1.12 |
| Forward PS | 0.4 |
| PB Ratio | -4.08 |
| P/FCF Ratio | -0.42 |
| PEG Ratio | n/a |
Enterprise Valuation
Plus Therapeutics Inc. has an Enterprise Value (EV) of 1.12M.
| EV / Earnings | -0.08 |
| EV / Sales | 0.23 |
| EV / EBITDA | -0.09 |
| EV / EBIT | -0.08 |
| EV / FCF | -0.09 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of -2.95.
| Current Ratio | 0.92 |
| Quick Ratio | 0.92 |
| Debt / Equity | -2.95 |
| Total Debt / Capitalization | 151.29 |
| Cash Flow / Debt | -3.23 |
| Interest Coverage | -33.72 |
Financial Efficiency
Return on equity (ROE) is 9.88% and return on capital (ROIC) is -470.21%.
| Return on Equity (ROE) | 9.88% |
| Return on Assets (ROA) | -1.17% |
| Return on Capital (ROIC) | -470.21% |
| Revenue Per Employee | 245.65K |
| Profits Per Employee | -665.80K |
| Employee Count | 20 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -43.48% in the last 52 weeks. The beta is 0.69, so Plus Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | -43.48% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 1.59 |
| Relative Strength Index (RSI) | 47.63 |
| Average Volume (20 Days) | 76.68K |
Income Statement
In the last 12 months, Plus Therapeutics had revenue of 4.91M and earned -13.32M in profits. Earnings per share was -4.24.
| Revenue | 4.91M |
| Gross Profit | -4.78M |
| Operating Income | -13.32M |
| Net Income | -13.32M |
| EBITDA | -12.69M |
| EBIT | -13.32M |
| Earnings Per Share (EPS) | -4.24 |
Balance Sheet
The company has 8.55M in cash and 4.18M in debt, giving a net cash position of 4.37M.
| Cash & Cash Equivalents | 8.55M |
| Total Debt | 4.18M |
| Net Cash | 4.37M |
| Retained Earnings | -480.50M |
| Total Assets | 6.98M |
| Working Capital | -6.75M |
Cash Flow
In the last 12 months, operating cash flow was -12.85M and capital expenditures -160.00K, giving a free cash flow of -13.01M.
| Operating Cash Flow | -12.85M |
| Capital Expenditures | -160.00K |
| Free Cash Flow | -13.01M |
| FCF Per Share | -4.14 |
Margins
Gross margin is -97.23%, with operating and profit margins of -271.14% and -271.04%.
| Gross Margin | -97.23% |
| Operating Margin | -271.14% |
| Pretax Margin | -271.04% |
| Profit Margin | -271.04% |
| EBITDA Margin | -258.36% |
| EBIT Margin | -271.14% |
| FCF Margin | -264.83% |
Dividends & Yields
PSTV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -362.39% |
| FCF Yield | -188.6% |
Analyst Forecast
The average price target for PSTV is $13.5, which is 1053.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.5 |
| Price Target Difference | 1053.8% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on May 1, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | May 1, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -104.41 |
| Piotroski F-Score | 2 |